CLARITY PHARMACEUTICALS LTD
ASX:CU6Pharmaceuticals, Biotechnology & Life SciencesToday’s holders own 92.7% of what they think they own, once every option and right converts.
Share count grew 18% in 24 months; runway 4–8 quarters; 1 cash raise in 24 months
CLARITY PHARMACEUTICALS LTD's ordinary share count grew 18.2% between September 2024 and July 2026, reaching 373M shares. In the past 24 months, the company has undertaken one capital raise, a placement in July 2025 that generated A$203.6M. Options and rights on issue could convert into 29M new shares, representing 7.9% of the current share count, though none are currently in the money. An expiry date for these securities is not on record. As of the June 2026 quarter, the company reported A$154.7M in available cash, providing approximately 5.3 quarters of operational runway. No proposed securities issues are currently pending.
Shares on issue — last 2 years
Cash runway
Issuance timeline
Latest 5 filings (Appendix 2A quoted issues, 3G unquoted, 3H cancellations)
| Date | Form | Security | On issue, per this filing | Source |
|---|---|---|---|---|
| 5 Aug 2026 | 3G · unquoted | ORDINARY FULLY PAID | 373.1M | Appendix 3G |
| 1 July 2026 | 2A · quoted issue | CU6 : ORDINARY FULLY PAID | 373.1M | Appendix 2A |
| 27 May 2026 | 3G · unquoted | ORDINARY FULLY PAID | 373.0M | Appendix 3G |
| 20 May 2026 | 2A · quoted issue | CU6 : ORDINARY FULLY PAID | 373.0M | Appendix 2A |
| 7 Apr 2026 | 3G · unquoted | ORDINARY FULLY PAID | 372.3M | Appendix 3G |
Capital raises
1 cash raise in the last 24 months · 0 in the last 12 months
Forward supply
Every dated event on record that could add securities to the register — option expiries to their stated dates and proposed issues over the next 18 months, on one timeline.
Placement capacity
How much stock a company can place without asking holders. Listing Rule 7.1 allows 15% of ordinary securities in any 12 months, and every Appendix 3B states how much of it an issue uses.
Pending proposed issues
Options & convertible securities
No option supply on record carries an exercise price to pay, so no share price switches any of it on. All 29.5M of it converts on something else — a hurdle that may never be met, or terms the filing does not price.
| Code | Security | Type | Exercise price | Expiry | On issue | Source |
|---|---|---|---|---|---|---|
| CU6AAM | Options | Price-triggered | — | — | 29.5M | Filing |
“Nil” is a stated nil exercise price: nothing is paid to convert. An em dash means the filing names no exercise price at all. Security is read from the filing’s own class description; an em dash there means the description is not one this table labels. One row is one security class, at the number stated in the most recent quotation application that restated it — linked, and dated, in the last column.
Director dealings
| Date | Director | Type | Shares | Options | Other | Value | Source |
|---|---|---|---|---|---|---|---|
| 20 Apr 2026 | Michelle Parker | Sell on-market | — | — | — | — | 3Y notice |
| 25 Nov 2025 | Alan John Taylor | Other | — | 1.3M | — | $2.0M | 3Y notice |
| 25 Nov 2025 | Colin David Biggin | Other | — | 487k | — | $788k | 3Y notice |
| 25 Nov 2025 | Michelle Parker | Other | — | 512k | — | $827k | 3Y notice |
Ownership
Latest announcements
Headlines link to the source PDFs on the ASX announcements platform. Data as of 12 Sept 2026.